Skip to content
Screener

Amphastar Pharmaceuticals AMPH Q2 2026 earnings

Reported August 6, 2026 · After market close

Revenue$183.9MBeat by $4.0M
EPS$0.91Beat by $0.29
Revenue estimate$179.9M
EPS estimate$0.62

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$197.9M
EPS estimate$0.86

Financials

Q2 2026

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.01B-18.8%
Enterprise value$1.47B-13.9%
P/E12.8×+3.6×
P/S1.4×-0.3×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Current ratio2.4×-0.9×

Segments

By geography

See full
US$172.3M+3.2%
FR$7.0M-1.6%
CN$4.6M+1,425%

By segment

See full
Finished Pharmaceutical Products$183.9M+5.4%

FAQ

When did Amphastar Pharmaceuticals report Q2 2026 earnings?
Amphastar Pharmaceuticals (AMPH) reported Q2 2026 earnings on August 6, 2026 after market close.
What were Amphastar Pharmaceuticals's Q2 2026 revenue and EPS?
Amphastar Pharmaceuticals reported revenue of $183.9M and eps of $0.91 for Q2 2026.
Did Amphastar Pharmaceuticals beat estimates in Q2 2026?
Revenue beat the consensus estimate of $179.9M by $4.0M. EPS beat the consensus estimate of $0.62 by $0.29.
How did Amphastar Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 5.4% from $174.4M a year earlier and eps grew 7.1% from $0.85.
Where can I find Amphastar Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001297184-26-000045) and the 10-Q periodic report (0001297184-26-000047) directly on SEC EDGAR. The filing index links above go to sec.gov.